Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Objectives To identify whether the outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in routine clinical practice have changed over time. Methods We analysed 12-month outcomes in treatment-naïve eyes that started afliberce...

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2023-04, Vol.37 (6), p.1145-1154
Main Authors: Bhandari, Sanjeeb, Nguyen, Vuong, Hunt, Adrian, Gabrielle, Pierre-Henry, Viola, Francesco, Mehta, Hemal, Manning, Les, Squirrell, David, Arnold, Jennifer, McAllister, Ian L., Barthelmes, Daniel, Gillies, Mark
Format: Article
Language:English
Subjects:
692/308/409
706/648/160
Age
Angiogenesis Inhibitors - therapeutic use
Clinical medicine
Diabetes
Diabetes Mellitus
Diabetic Retinopathy - complications
Diabetic Retinopathy - drug therapy
Edema
Eye
Humans
Intravitreal Injections
Laboratory Medicine
Macular degeneration
Macular Degeneration - drug therapy
Macular Edema - drug therapy
Macular Edema - etiology
Medicine
Medicine & Public Health
Occlusion
Ophthalmology
Pharmaceutical Sciences/Technology
Ranibizumab - therapeutic use
Retina
Retinal Vein Occlusion - complications
Retinal Vein Occlusion - drug therapy
Retrospective Studies
Surgery
Surgical Oncology
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To identify whether the outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in routine clinical practice have changed over time. Methods We analysed 12-month outcomes in treatment-naïve eyes that started aflibercept or ranibizumab for nAMD (3802 eyes), DMO (975 eyes), Branch RVO (BRVO, 357 eyes), Central RVO (CRVO, 371 eyes) and Hemi-RVO (HRVO, 54 eyes) from 2015 and 2019 tracked in the prospectively designed observational Fight Retinal Blindness! Registry. Results The mean VA change at 12-month for each year between 2015 and 2019 remained stable or otherwise showed no discernible trends over time in eyes with nAMD (+3.3 to +6 letters), DMO (+3.6 to +6.7 letters) and RVO (+10.3 to +11.7 letters for BRVO, +5.9 to +17.7 letters for CRVO and 10.2 to 20.7 letters for HRVO). The median number of VEGF-inhibitor injections in eyes that completed 12-month follow-up also remained stable at 8–9 for nAMD, 6–7 for DMO, 7–9 for RVO. Fewer eyes (
ISSN:0950-222X
1476-5454
DOI:10.1038/s41433-022-02075-6